Key result
Desmopressin resolves post-bypass microvascular bleeding and restores platelet aggregation without requiring blood transfusion.
Why the study?
Only 18 patients with impaired platelet response to ADP have been described, none in the high bleeding-risk surgical setting or exploring potential therapeutic options.
Does intravenous desmopressin improve platelet function and control microvascular bleeding in a patient with impaired platelet response to ADP undergoing on-pump cardiac surgery?
Case Report (n=1)
No
Does intravenous desmopressin improve platelet function and control microvascular bleeding in a patient with impaired platelet response to ADP undergoing on-pump cardiac surgery?
Demonstrates for the first time in on-pump cardiac surgery that preoperative multiple electrode aggregometry can identify impaired platelet response to ADP and that intravenous desmopressin (0.3 μg/kg) can effectively manage resulting microvascular bleeding without platelet transfusions.
May support desmopressin for ADP-impaired bleeding in cardiac surgery; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Impairment of platelet responses to adenosine diphosphate (ADP) is typified by mild to severe bleeding diathesis, easy bruising, excessive mucosal and post-operative bleeding. Patients lack full platelet activation and aggregation in response to ADP. Following research of the literature in Scopus, PubMed/MEDLINE, ScienceDirect, and the Cochrane Library, we report only 18 patients described to date with impaired platelet response to ADP, none of whom in the high bleeding-risk surgical setting or exploring potential therapeutic options. Data regarding population, putative genetic mutations, modes of inheritance, functional defects, and related clinical manifestations were retrieved from case series and case reports. CASE PRESENTATION: Roche Diagnostics, Rotkreuz, Switzerland) was used to evaluate platelet response to thrombin-activated peptide-6 (TRAP), arachidonic acid (ASPI), and ADP. An inadequate platelet aggregation induced using a high concentration of ADP with normal TRAP and ASPI tests was detected preoperatively. Therefore, intravenous desmopressin (DVVAP) 0.3 μg/kg body weight was administered to manage microvascular bleeding developed after weaning from cardiopulmonary bypass (CPB). CONCLUSIONS: Proper management of impaired platelet response to ADP requires a systematic assessment. The Multiplate analyzer is a valuable tool to promptly detect the disorder when a high clinical suspect is present and obtain insights during high bleeding-risk surgical procedures. DVVAP can be beneficial as first-line therapy in bleeding patients to improve platelet function.
No takes yet. Share an insight, caveat, or question.
Ursoleo et al. (2023) conducted a case report in Impairment of platelet responses to adenosine diphosphate (ADP) and severe aortic valve regurgitation (n=1). Desmopressin was evaluated on Management of microvascular bleeding and improvement of platelet function assessed via multiple electrode aggregometry (Multiplate analyzer). Intravenous desmopressin (0.3 μg/kg) improved ADP-induced platelet aggregation AUC to 27 U and resolved microvascular bleeding without transfusions in a patient with impaired ADP platelet response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: